GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients

Clinical Immunology

Volumn 176, Issue , 2017, Pages 114-121

  Pihl, Mikael ^a   Barcenilla, Hugo ^a   Axelsson, Stina ^a   Chéramy, Mikael ^a   Åkerman, Linda ^a   Johansson, Ingela ^a   Ludvigsson, Johnny ^a   Casas, Rosaura ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Children; GAD; Immune intervention; Regulatory T cells; Type 1 diabetes

Indexed keywords

ALUMINUM HYDROXIDE; GLUTAMATE DECARBOXYLASE 65; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; PLACEBO; TETRAMER; GLUTAMATE DECARBOXYLASE; INTERLEUKIN 7 RECEPTOR ALPHA;

ADOLESCENT; ARTICLE; CD25+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; DIABETIC PATIENT; EFFECTOR CELL; HUMAN; IMMUNOPHENOTYPING; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SWEDE (PEOPLE); T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ADULT; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; FOLLOW UP; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SWEDEN; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLUTAMATE DECARBOXYLASE; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MALE; SWEDEN; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 85010832206     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2017.01.010     Document Type: Article

References (27)

1. [1] Atkinson, M.A., Maclaren, N.K., The pathogenesis of insulin-dependent diabetes mellitus. N. Engl. J. Med. 331 (1994), 1428–1436.
2. [2] Mallone, R., van Endert, P., T cells in the pathogenesis of Type 1 diabetes. Curr. Diab. Rep. 8 (2008), 101–106.
3. [3] Ludvigsson, J., Adequate doses of autoantigen administered using the appropriate route may create tolerance and stop autoimmunity. Diabetologia 52 (2009), 175–176.
4. [4] Baekkeskov, S., Aanstoot, H.J., Christgau, S., Reetz, A., Solimena, M., Cascalho, M., Folli, F., Richter-Olesen, H., De Camilli, P., Identification of the 64 K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347 (1990), 151–156.
5. [5] Ludvigsson, J., Faresjo, M., Hjorth, M., Axelsson, S., Cheramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., Lindh, A., Nilsson, N.O., Aman, J., Ortqvist, E., Zerhouni, P., Casas, R., GAD treatment and insulin secretion in recent-onset Type 1 diabetes. N. Engl. J. Med. 359 (2008), 1909–1920.
6. 65 immunomodulation in adult-onset autoimmune diabetes. J. Diabetes Complicat. 19 (2005), 238–246.
7. [7] Wherrett, D.K., Bundy, B., Becker, D.J., DiMeglio, L.A., Gitelman, S.E., Goland, R., Gottlieb, P.A., Greenbaum, C.J., Herold, K.C., Marks, J.B., Monzavi, R., Moran, A., Orban, T., Palmer, J.P., Raskin, P., Rodriguez, H., Schatz, D., Wilson, D.M., Krischer, J.P., Skyler, J.S., Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset Type 1 diabetes: a randomised double-blind trial. Lancet 378 (2011), 319–327.
8. [8] Ludvigsson, J., Hjorth, M., Cheramy, M., Axelsson, S., Pihl, M., Forsander, G., Nilsson, N.O., Samuelsson, B.O., Wood, T., Aman, J., Ortqvist, E., Casas, R., Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset Type 1 diabetes: a randomised controlled trial. Diabetologia 54 (2011), 634–640.
9. [9] Axelsson, S., Hjorth, M., Akerman, L., Ludvigsson, J., Casas, R., Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65). Diabetes Metab. Res. Rev. 26 (2010), 559–568.
10. [10] Axelsson, S., Cheramy, M., Hjorth, M., Pihl, M., Akerman, L., Martinuzzi, E., Mallone, R., Ludvigsson, J., Casas, R., Long-lasting immune responses 4 years after GAD-alum treatment in children with Type 1 diabetes. PLoS One, 6, 2011, e29008.
11. 65 enzyme activity and humoral response. Clin. Immunol. 137 (2010), 31–40.
12. [12] Pihl, M., Akerman, L., Axelsson, S., Cheramy, M., Hjorth, M., Mallone, R., Ludvigsson, J., Casas, R., Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with Type 1 diabetes. Clin. Exp. Immunol. 172 (2013), 394–402.
13. 65-specific CD4 + CD25highFOXP3 + cells in type 1 diabetic patients. Clin. Immunol. 138 (2011), 117–126.
14. 65 antigen therapy in recently diagnosed Type 1 diabetes mellitus. N. Engl. J. Med. 366 (2012), 433–442.
15. [15] Ludvigsson, J., Cheramy, M., Axelsson, S., Pihl, M., Akerman, L., Casas, R., G.A.D.s.g.i.S. clinical, GAD-treatment of children and adolescents with recent-onset Type 1 diabetes preserves residual insulin secretion after 30 months. Diabetes Metab. Res. Rev. 30 (2014), 405–414.
16. [16] Smilek, D.E., Ehlers, M.R., Nepom, G.T., Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis. Model. Mech. 7 (2014), 503–513.
17. [17] Matthews, J.B., Staeva, T.P., Bernstein, P.L., Peakman, M., von Herrath, M., I.-J. Group, Developing combination immunotherapies for Type 1 diabetes: recommendations from the ITN-JDRF Type 1 diabetes Combination Therapy Assessment Group. Clin. Exp. Immunol. 160 (2010), 176–184.
18. [18] DIAPREV-IT study of diabetes therapy Diamyd(R) receives further funding and will continue despite disappointing Phase III trial results. Immunotherapy, 3, 2011, 923–924.
19. 65 protect insulin-production in the pancreatic islet beta cells?. Hum. Vaccin. 7 (2011), 45–49.
20. [20] Axelsson, S., Chéramy, M., Akerman, L., Pihl, M., Ludvigsson, J., Casas, R., Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial. Diabetes Care 36 (2013), 3418–3424.
21. [21] Gersuk, V.H., Nepom, G.T., A real-time PCR approach for rapid high resolution subtyping of HLA-DRB1*04. J. Immunol. Methods 317 (2006), 64–70.
22. [22] Putnam, A.L., Brusko, T.M., Lee, M.R., Liu, W., Szot, G.L., Ghosh, T., Atkinson, M.A., Bluestone, J.A., Expansion of human regulatory T-cells from patients with Type 1 diabetes. Diabetes 58 (2009), 652–662.
23. [23] Axelsson, S., Cheramy, M., Akerman, L., Pihl, M., Ludvigsson, J., Casas, R., Cellular and humoral immune responses in Type 1 Diabetic patients participating in a phase III GAD-alum intervention trial. Diabetes Care 36 (2013), 3418–3424.
24. [24] Malek, T.R., Castro, I., Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33 (2010), 153–165.
25. [25] Lawson, J.M., Tremble, J., Dayan, C., Beyan, H., Leslie, R.D.G., Peakman, M., Tree, T.I.M., Increased resistance to CD4 + CD25hi regulatory T cell-mediated suppression in patients with Type 1 diabetes. Clin. Exp. Immunol. 154 (2008), 353–359.
26. [26] Schneider, A., Rieck, M., Sanda, S., Pihoker, C., Greenbaum, C., Buckner, J.H., The effector T cells of diabetic subjects are resistant to regulation via CD4 + FOXP3 + regulatory T cells. J. Immunol. 181 (2008), 7350–7355.
27. [27] Bluestone, J.A., Buckner, J.H., Fitch, M., Gitelman, S.E., Gupta, S., Hellerstein, M.K., Herold, K.C., Lares, A., Lee, M.R., Li, K., Liu, W., Long, A.S., Masiello, L.M., Nguyen, V., Putnam, A.L., Rieck, M., Sayre, P.H., Tang, Q., Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med., 7, 2015.